NEW: The FDA has authorized a new monoclonal anitbody, Pemgarda, to protect immunocompromised individuals (like transplant recipients & those with heme malignancies). against Covid-19. Immunocomp individuals have a higher risk of severe outcomes.
https://www.statnews.com/2024/03/22/covid-immunocompromised-antibody-protection-invivyd/
#COVID #COVID19 #monoclonal #medtwitter
Carolyn Barber, MD /
npub17a…8ydzp
2024-03-24 18:57:18
Author Public Key
npub17aet92c7rt96vy82n33kckddwulf6ecygejwgu8669kj7367zg9sw8ydzpPublished at
2024-03-24 18:57:18Event JSON
{
"id": "8c69856c550e670b13ed3637f476cc3eff94e26dfcaf13496f0d57a4ca941e19",
"pubkey": "f772b2ab1e1acba610ea9c636c59ad773e9d67044664e470fad16d2f475e120b",
"created_at": 1711303038,
"kind": 1,
"tags": [
[
"t",
"COVID"
],
[
"t",
"COVID19"
],
[
"t",
"monoclonal"
],
[
"t",
"medtwitter"
],
[
"proxy",
"https://med-mastodon.com/users/cbarbermd/statuses/112151955903180069",
"activitypub"
]
],
"content": "NEW: The FDA has authorized a new monoclonal anitbody, Pemgarda, to protect immunocompromised individuals (like transplant recipients \u0026 those with heme malignancies). against Covid-19. Immunocomp individuals have a higher risk of severe outcomes. \n\nhttps://www.statnews.com/2024/03/22/covid-immunocompromised-antibody-protection-invivyd/\n#COVID #COVID19 #monoclonal #medtwitter",
"sig": "51e317e337eee27d7e60618719b6c1b072c28daa43cc0a8c40827cf4b1a866d3daa0bbe7b33e2790a538959adfa19eebe47bb708f4bf371d5200eb142c8dc6da"
}